Literature DB >> 24014152

Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.

Stephanie J DeWard1, Ashley Wilson, Heather Bausell, Ashley S Volz, Kimberly Mooney.   

Abstract

Bringing treatments for rare genetic diseases to patients requires clinical research. Despite increasing activism from patient support and advocacy groups to increase access to clinical research studies, connecting rare disease patients with the clinical research opportunities that may help them has proven challenging. Chief among these challenges are the low incidence of these diseases resulting in a very small pool of known patients with a particular disease, difficulty of diagnosing rare genetic diseases, logistical issues such as long distances to the nearest treatment center, and substantial disease burden leading to loss of independence. Using clinical studies of phenylketonuria as an example, this paper discusses how, based on the authors' collective experience, partnership among clinicians, patients, study coordinators, genetic counselors, dietitians, industry, patient support groups, and families can help overcome the challenges of recruiting and retaining patients in rare disease clinical trials. We discuss specific methods of collaboration, communication, and education as part of a long-term effort to build a community committed to advancing the medical care of patients with rare genetic diseases. By talking to patients and families regularly about research initiatives and taking steps to make study participation as easy as possible, rare disease clinic staff can help ensure adequate study enrollment and successful study completion.

Entities:  

Mesh:

Year:  2013        PMID: 24014152     DOI: 10.1007/s10897-013-9642-y

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  8 in total

1.  PKU adults and their return to diet: predicting diet continuation and maintenance.

Authors:  L Finkelson; I Bailey; S E Waisbren
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

Review 2.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

3.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

4.  Spontaneous coronary artery dissection: a disease-specific, social networking community-initiated study.

Authors:  Marysia S Tweet; Rajiv Gulati; Lee A Aase; Sharonne N Hayes
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

5.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

6.  Improving subject recruitment, retention, and participation in research through Peplau's theory of interpersonal relations.

Authors:  Sue Penckofer; Mary Byrn; Patricia Mumby; Carol Estwing Ferrans
Journal:  Nurs Sci Q       Date:  2011-04       Impact factor: 0.883

7.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

Review 8.  Strategies for increasing recruitment to randomised controlled trials: systematic review.

Authors:  Patrina H Y Caldwell; Sana Hamilton; Alvin Tan; Jonathan C Craig
Journal:  PLoS Med       Date:  2010-11-09       Impact factor: 11.069

  8 in total
  10 in total

1.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

Review 2.  A systematic review of approaches for engaging patients for research on rare diseases.

Authors:  Laura P Forsythe; Victoria Szydlowski; Mohammad Hassan Murad; Stanley Ip; Zhen Wang; Tarig A Elraiyah; Rachael Fleurence; David H Hickam
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

3.  What role can decentralized trial designs play to improve rare disease studies?

Authors:  J Moore; N Goodson; P Wicks; J Reites
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

4.  A Roadmap to Patient Engagement: Facioscapulohumeral Muscular Dystrophy and the ReSolve Clinical Trial.

Authors:  Samantha LoRusso; Katy Eichinger; Kiley Higgs; Leann Lewis; Michaela Walker; James Albert; Michele Langer; Rabi Tawil; Jeffrey M Statland; Kim S Kimminau
Journal:  Neurol Clin Pract       Date:  2021-10

5.  A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.

Authors:  Alexander Masters; Dominic Nutt
Journal:  J Med Ethics       Date:  2017-06-06       Impact factor: 2.903

6.  Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research.

Authors:  Kylie Tingley; Doug Coyle; Ian D Graham; Pranesh Chakraborty; Kumanan Wilson; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2021-01-12       Impact factor: 4.123

7.  Patient's thoughts and expectations about centres of expertise for PKU.

Authors:  A M J van Wegberg; A MacDonald; D Abeln; T S Hagedorn; E Lange; F Trefz; D van Vliet; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

8.  Challenges Faced by Behavioral Genetic Studies: Researchers Perspective from the MENA Region.

Authors:  Omar F Khabour; Ahmed A Abu-Siniyeh; Karem H Alzoubi; Nihaya A Al-Sheyab
Journal:  Curr Genomics       Date:  2021-12-31       Impact factor: 2.689

9.  Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.

Authors:  Ying Hong Li; Xiao Xu Li; Jia Jun Hong; Yun Xia Wang; Jian Bo Fu; Hong Yang; Chun Yan Yu; Feng Cheng Li; Jie Hu; Wei Wei Xue; Yu Yang Jiang; Yu Zong Chen; Feng Zhu
Journal:  Brief Bioinform       Date:  2020-03-23       Impact factor: 11.622

Review 10.  Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.

Authors:  Lars Schlotawa; Laura A Adang; Karthikeyan Radhakrishnan; Rebecca C Ahrens-Nicklas
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.